Non Invasive Prenatal Testing (NIPT) Market worth 2.88 Billion USD by 2021

on
The global Non Invasive Prenatal Testing Market is expected to reach USD 2.88 Billion by 2021 from USD 1.35 Billion in 2016, at a CAGR of 16.4% during the forecast period.
The major factors driving the growth of this market include the growing preference for non-invasive techniques over invasive methods, rising focus on reimbursement for NIPT, launch of new and advanced NIPT products, and increasing maternal age (associated with growth in the risk of chromosomal abnormalities in babies). Furthermore, untapped emerging markets are expected to offer potential growth opportunities to players operating in the NIPT market during the forecast period.
Based on method, the market is classified into ultrasound detection, biochemical screening tests, fetal cells in maternal blood tests, and cell-free DNA in maternal plasma tests. In 2016, the ultrasound detection accounted for the largest share of the market. The cell-free DNA in maternal plasma tests segment is expected to grow at the highest CAGR during the forecast period. The increasing demand for cf-DNA based techniques in NIPT testing and rising government initiatives to provide prenatal services are the factors contributing to the growth of this market.
Based on end user, the NIPT market is segmented into diagnostic laboratories and hospitals. In 2016, the diagnostic laboratories segment accounted for the largest share of the market. Growth in this end-user segment can be attributed to the rising incidence of chromosomal abnormalities and initiatives by companies to provide technologically advanced products to diagnostic laboratories.
The market is highly fragmented with several big and emerging players. Key market players include GE Healthcare (U.S.), Koninklijke Philips N.V. (Netherlands), Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Pacific Biosciences of California, Inc. (U.S.), PerkinElmer, Inc. (U.S.), QIAGEN N.V. (Germany), Agilent Technologies, Inc. (U.S.), and Beijing Genomics Institute (China).

Comments

Post a Comment